<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318785</url>
  </required_header>
  <id_info>
    <org_study_id>Multicentrestudy &quot;BF09-PH-01&quot;</org_study_id>
    <nct_id>NCT01318785</nct_id>
  </id_info>
  <brief_title>Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications</brief_title>
  <acronym>BF09-PH-01</acronym>
  <official_title>Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications (Therapeutische Bewertung Von Armkompressionsstrümpfen für Lymphatische Indikationen BF09-PH-01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KABEG Management</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nij Smellinghe Hosptial</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medicine Greifswald</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examination of therapeutical effects of different types of armsleeves in treating lymphatic&#xD;
      diseases after breast cancer surgery during maintenance phase&#xD;
&#xD;
        1. thesis:&#xD;
&#xD;
           - all types should be equal regarding volume reduction&#xD;
&#xD;
        2. thesis: armsleeves manufactured with microfibre yarn are expected to be&#xD;
&#xD;
             -  better in wearing comfort and&#xD;
&#xD;
             -  better in handling features.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. thesis:&#xD;
&#xD;
             -  measuring of arm volume by &quot;inverse water-volumetry&quot; (see later)&#xD;
&#xD;
             -  measuring of circumference cD&#xD;
&#xD;
             -  measuring of circumference cG&#xD;
&#xD;
             -  photodocumentation in 2 positions(during each round)&#xD;
&#xD;
        2. thesis&#xD;
&#xD;
             -  questionaire for patients&#xD;
&#xD;
                  -  in the beginning&#xD;
&#xD;
                  -  after 1 week&#xD;
&#xD;
                  -  after 2 weeks (at the end of a wearing period)&#xD;
&#xD;
             -  questionaire for study nurse (at the end of a wearing period)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">November 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of volume (arm and hand together)</measure>
    <time_frame>6 weaks per patient</time_frame>
    <description>During a 2-weeks-phase the volume of patients arm and hand together is measured once a week, e.g. 3 times (beginning, after 1 week, at the end).&#xD;
This is done with armsleeves of the first type. After one week of sedation the test will be repeated with the second product.&#xD;
Randomization is given by chance, that during first phase product of type A or type B can be applied. During second phase then vice versa.&#xD;
The measurements were performed by an &quot;inverse water plethysmography device&quot; (later: inverse watervolumetry) desinged by R. Damstra.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical judgement of skin status</measure>
    <time_frame>6 weaks per patient</time_frame>
    <description>clinical judgement of skin status with photo documentation, clinical finding (as palpation,check on fibrosclerosis, skin clour, skin surface, edema, tenderness, tissue consistency...), check of skin contamination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wearing comfort and handling features of armsleeves</measure>
    <time_frame>6 weeks per patient</time_frame>
    <description>For both types of products questionaires are prepared to find out how patients are feeling with their armsleeves.It is asked for problems during donning procedure as well as during wearing period. This will be done in the beginning after 1 week and after 2 weeks for both types.&#xD;
At the end the study nurses are asked to their impression regarding patients acceptance of the armsleeves.&#xD;
Method: VAS score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>Compression ArmsleevesType A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Product A: armsleeves of type SoraLife KKl. 2 according to RAL GZ 387</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Compression Armsleeves Type B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Product B: armsleeves of type Elvarex KKl. 2 according to RAL GZ 387</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Compression Armsleeves</intervention_name>
    <description>Type: Compression Class II (according to RAL)&#xD;
The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient.</description>
    <arm_group_label>Compression Armsleeves Type B</arm_group_label>
    <arm_group_label>Compression ArmsleevesType A</arm_group_label>
    <other_name>Bauerfeind SoraLife</other_name>
    <other_name>Jobst Elvarex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women with a secondary arm-lymphedema for at least 3 months&#xD;
&#xD;
          -  willingness to wear compression arm-sleeves for at least 12 hours per day&#xD;
&#xD;
          -  maintenance phase, where no significant further reduction of arm-volume can be&#xD;
             achieved&#xD;
&#xD;
          -  lymphedema in stadium 1 or 2&#xD;
&#xD;
          -  age: at least 18 years&#xD;
&#xD;
          -  signed consent form by the patient&#xD;
&#xD;
          -  sufficient knowledge in national language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  edema not completely reduced to &quot;maintenance phase&quot;&#xD;
&#xD;
          -  immobilized patient&#xD;
&#xD;
          -  acute deep vein thrombosis in arm&#xD;
&#xD;
          -  directly after arm-vein-thrombosis&#xD;
&#xD;
          -  acute arm erysipelas&#xD;
&#xD;
          -  malignant edema&#xD;
&#xD;
          -  existent lipedema&#xD;
&#xD;
          -  arterial occlusion&#xD;
&#xD;
          -  distinctive neuropathy in upper limbs&#xD;
&#xD;
          -  neurinoma in upper limbs&#xD;
&#xD;
          -  chronic pain after plastic surgery in upper limbs, shoulder or breast&#xD;
&#xD;
          -  change in drug treatment, that can influence edema situation during the study&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  breast giving mothers&#xD;
&#xD;
          -  not signed consent form&#xD;
&#xD;
          -  participation in a second clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Jünger, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik und Poliklinik für Hautkrankheiten der Universität Greifswald</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Jünger, Prof. Dr.</last_name>
    <phone>+493834-866770</phone>
    <email>juenger@uni-greifswald.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Eggert, Study Nurse</last_name>
    <phone>+493834-866770</phone>
    <email>claudia.eggert@uni-greifswald.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Landeskrankenhaus Wolfsberg</name>
      <address>
        <city>Wolfsberg</city>
        <state>Kärnten</state>
        <zip>9400</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Döller, MD</last_name>
      <email>sekretariatlymph@lkh-wo.at</email>
    </contact>
    <investigator>
      <last_name>Walter Döller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Flour, MD</last_name>
      <email>maria.flour@uz.kuleuven.ac.be</email>
    </contact>
    <investigator>
      <last_name>Maria Flour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Hautkrankheiten, Sauerbruchstraße</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg Vorpommern</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jünger, Prof. Dr.</last_name>
      <phone>+493834-866770</phone>
      <email>juenger@uni-greifswald.de</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Eggert, Study Nurse</last_name>
      <phone>+493834-866770</phone>
      <email>claudia.eggert@uni-greifswald.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nij Smellinghe Hosptial</name>
      <address>
        <city>Drachten</city>
        <zip>9202</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Damstra, MD</last_name>
      <email>r.damstra@nijsmellinghe.nl</email>
    </contact>
    <investigator>
      <last_name>Robert Damstra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.medizin.uni-greifswald.de/haut/</url>
    <description>link to Greifswald dermatology</description>
  </link>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>December 3, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <last_update_submitted>September 5, 2011</last_update_submitted>
  <last_update_submitted_qc>September 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. Michael Jünger</name_title>
    <organization>Klinik und Poliklinik für Hautkrankheiten der Universität Greifswald</organization>
  </responsible_party>
  <keyword>secondary arm-lymphedema</keyword>
  <keyword>breast cancer related arm-lymphedema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

